Synonyms: compound 52 [4] | Lu AE58054 | LU-AE58054
Compound class:
Synthetic organic
Comment: Idalopirdine is a serotonin 5-HT6 receptor antagonist [4].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Benhamú B, Martín-Fontecha M, Vázquez-Villa H, Pardo L, López-Rodríguez ML. (2014)
Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease. J Med Chem, 57 (17): 7160-81. [PMID:24850589] |
2. Galimberti D, Scarpini E. (2015)
Idalopirdine as a treatment for Alzheimer's disease. Expert Opin Investig Drugs, 24 (7): 981-7. [PMID:26022777] |
3. Geldenhuys WJ, Van der Schyf CJ. (2008)
Serotonin 5-HT6 receptor antagonists for the treatment of Alzheimer's disease. Curr Top Med Chem, 8 (12): 1035-48. [PMID:18691131] |
4. Krogsgaard-Larsen N, Jensen AA, Schrøder TJ, Christoffersen CT, Kehler J. (2014)
Novel aza-analogous ergoline derived scaffolds as potent serotonin 5-HT₆ and dopamine D₂ receptor ligands. J Med Chem, 57 (13): 5823-8. [PMID:24878269] |
5. Rossé G, Schaffhauser H. (2010)
5-HT6 receptor antagonists as potential therapeutics for cognitive impairment. Curr Top Med Chem, 10 (2): 207-21. [PMID:20166958] |
6. Wilkinson D, Windfeld K, Colding-Jørgensen E. (2014)
Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol, 13 (11): 1092-9. [PMID:25297016] |